{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:01:59Z","timestamp":1789408919835,"version":"build-2803163510"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["SYH2055"],"award-info":[{"award-number":["SYH2055"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["ASC-11"],"award-info":[{"award-number":["ASC-11"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["NCT05718518"],"award-info":[{"award-number":["NCT05718518"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["PF-07817883"],"award-info":[{"award-number":["PF-07817883"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["ABBV-903"],"award-info":[{"award-number":["ABBV-903"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["NCT05716425"],"award-info":[{"award-number":["NCT05716425"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["STI-1558"],"award-info":[{"award-number":["STI-1558"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["NCT05799495"],"award-info":[{"award-number":["NCT05799495"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["NCT05895266"],"award-info":[{"award-number":["NCT05895266"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["ISM-3312"],"award-info":[{"award-number":["ISM-3312"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2020CGXNG-044"],"award-info":[{"award-number":["2020CGXNG-044"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ \\u2212779"],"award-info":[{"award-number":["2019JQ \\u2212779"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2021-02-220-020"],"award-info":[{"award-number":["2021-02-220-020"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2022-QCYZH-013"],"award-info":[{"award-number":["2022-QCYZH-013"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2022-QCYZH-033"],"award-info":[{"award-number":["2022-QCYZH-033"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["022-SLRH-YQ-009"],"award-info":[{"award-number":["022-SLRH-YQ-009"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2022-QCYZH-032"],"award-info":[{"award-number":["2022-QCYZH-032"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010228","name":"Natural Science Foundation of Shaanxi Provincial Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273268"],"award-info":[{"award-number":["52273268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803784"],"award-info":[{"award-number":["81803784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200315"],"award-info":[{"award-number":["32200315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373843"],"award-info":[{"award-number":["82373843"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.115979","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T07:12:34Z","timestamp":1700896354000},"page":"115979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection"],"prefix":"10.1016","volume":"264","author":[{"given":"Lei","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuding","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-8998","authenticated-orcid":false,"given":"Chengyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115979_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0140-6736(23)00050-8","article-title":"The COVID-19 pandemic in 2023: far from over","volume":"401","author":"The","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115979_bib3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/eurheartj\/ehac168","article-title":"SARS-CoV-2 infection markedly increases long-term cardiovascular risk","volume":"43","author":"Liuzzo","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2023.115979_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.13560","article-title":"Factors influencing the immune response over 15 months after SARS-CoV-2 infection: a longitudinal population-wide study in the Faroe Islands","volume":"293","author":"Petersen","year":"2023","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005957","article-title":"SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report","volume":"11","author":"McNerney","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ejmech.2023.115979_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.219","article-title":"Cardiac impairment in Long Covid 1-year post SARS-CoV-2 infection","volume":"43","author":"Roca-Fernandez","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2023.115979_bib7","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41591-022-02001-z","article-title":"Long-term neurologic outcomes of COVID-19","volume":"28","author":"Xu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115979_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/j.pain.0000000000002711","article-title":"A comparison of pain, fatigue, and function between post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study","volume":"164","author":"Haider","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2023.115979_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurheartj\/ehac031","article-title":"Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus","volume":"43","author":"Raman","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2023.115979_bib12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0140-6736(21)02323-0","article-title":"Long-term effects on survivors with COVID-19","volume":"398","author":"Yang","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115979_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053403","article-title":"Elucidating symptoms of COVID-19 illness in the Arizona CoVHORT: a longitudinal cohort study","volume":"12","author":"Khan","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejmech.2023.115979_bib14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41591-022-01837-9","article-title":"A multisystem, cardio-renal investigation of post-COVID-19 illness","volume":"28","author":"Morrow","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004194","article-title":"Prevalence and characteristics of long COVID in elderly patients: an observational cohort study of over 2 million adults in the US","volume":"20","author":"Fung","year":"2023","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib16","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1503\/cmaj.220823","article-title":"Assessing common and potentially modifiable symptoms of post-COVID-19 condition (long COVID) in adults","volume":"195","author":"Kieran","year":"2023","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ejmech.2023.115979_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s15010-021-01666-x","article-title":"Long COVID, a comprehensive systematic scoping review","volume":"49","author":"Akbarialiabad","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.ejmech.2023.115979_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34803","article-title":"Association of SARS-CoV-2 infection with psychological distress, psychotropic prescribing, fatigue, and sleep problems among UK primary care patients","volume":"4","author":"Abel","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2023.115979_bib19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7150\/thno.79902","article-title":"Dynamic white matter changes in recovered COVID-19 patients: a two-year follow-up study","volume":"13","author":"Huang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2023.115979_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(22)00169-2","article-title":"A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study","volume":"10","author":"Munblit","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jconrel.2023.02.011","article-title":"Recent advances in respiratory immunization: a focus on COVID-19 vaccines","volume":"355","author":"He","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2023.115979_bib28","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/s41467-023-37926-7","article-title":"Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib29","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115979_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40820-021-00771-8","article-title":"From bench to the clinic: the path to translation of nanotechnology-enabled mRNA SARS-CoV-2 vaccines","volume":"14","author":"Lopez-Cantu","year":"2022","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib31","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/S0735-1097(23)03991-8","article-title":"COVID-19 versus immune checkpoint inhibitor myocarditis: a clinical dilemma","volume":"81","author":"Dewaswala","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2023.115979_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103455","article-title":"Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR","volume":"69","author":"Wagenh\u00e4user","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2023.115979_bib33","article-title":"Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2","volume":"13","author":"Karuppaiah","year":"2023","journal-title":"Biosens. Bioelectron. X"},{"key":"10.1016\/j.ejmech.2023.115979_bib34","article-title":"Research progress of severe acute respiratory syndrome coronavirus 2 on aerosol collection and detection","author":"Zhang","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib35","article-title":"Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms","author":"Tang","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2023.115979_bib37","first-page":"203","article-title":"Repurposing metabolic drugs for COVID-19","volume":"23","author":"Bordon","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115979_bib38","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1016\/j.apsb.2023.02.010","article-title":"Regulating the microenvironment with nanomaterials: potential strategies to ameliorate COVID-19","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115979_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12929-022-00852-9","article-title":"A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies","volume":"29","author":"Kumari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib42","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115979_bib47","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115979_bib48","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115979_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11427-021-1964-4","article-title":"Overview of SARS-CoV-2 genome-encoded proteins","volume":"65","author":"Bai","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115979_bib53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s11224-022-02089-6","article-title":"Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations","volume":"34","author":"Parmar","year":"2022","journal-title":"Struct. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115979_bib55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","article-title":"The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition","volume":"32","author":"Sacco","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100029","article-title":"Emerging SARS-CoV-2 variants: why, how, and what's next?","volume":"1","author":"Chen","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.ejmech.2023.115979_bib58","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib59","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1038\/s41467-021-23751-3","article-title":"Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease","volume":"12","author":"Su","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib60","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure\u2013activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib61","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib62","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3cl proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib63","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2023.115979_bib65","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/14756366.2021.1954919","article-title":"Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332","volume":"36","author":"Pavan","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acscentsci.2c00369","article-title":"The path to Paxlovid","volume":"8","author":"Halford","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib67","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib68","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib69","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib70","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115979_bib72","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41598-022-05424-3","article-title":"Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19","volume":"12","author":"Abe","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115979_bib73","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115979_bib75","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115979_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2023.115979_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib78","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115979_bib81","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01229-22","article-title":"Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis","volume":"66","author":"Lingscheid","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115979_bib83","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/d41586-022-00112-8","article-title":"Why scientists are racing to develop more COVID antivirals","volume":"601","author":"Kozlov","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115979_bib84","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib85","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2022.9925","article-title":"From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take Paxlovid","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2023.115979_bib86","series-title":"COVID-19 Rebound after Paxlovid and Molnupiravir during January-June 2022","first-page":"2022","author":"Lindsey","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib87","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1093\/cid\/ciac496","article-title":"Virologic and immunologic characterization of coronavirus disease 2019 recrudescence after nirmatrelvir\/ritonavir treatment","volume":"76","author":"Carlin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115979_bib89","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial, the Lancet regional health","volume":"38","author":"Wang","year":"2023","journal-title":"Western Pacific"},{"key":"10.1016\/j.ejmech.2023.115979_bib91","series-title":"Functionalized Peptides for Inhibition of Coronavirus 3C or 3C-like Protease and for Treatment and Prevention of Coronavirus Infection","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib92","series-title":"Preparation of Peptidomimetics as RNA Virus Inhibitors, Especially SARS-CoV-2 3CL Protease Inhibitors, and Their Uses for Treating a Viral Infection","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib96","series-title":"Preparation of Macrocyclic Spiropyrrolidine Derived Antiviral Agents","first-page":"US11319325","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib97","series-title":"Pharmaceutical Use of Aldehyde-Based Compound","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115979_bib98","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105450","article-title":"In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2","volume":"208","author":"Shang","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115979_bib101","series-title":"Novel Coronavirus Main Protease Inhibitor, and Preparation Method Therefor and Use Thereof","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114570","article-title":"A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Ma","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114596","article-title":"A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Alugubelli","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib104","doi-asserted-by":"crossref","first-page":"11040","DOI":"10.1021\/acs.jmedchem.3c00221","article-title":"A systematic survey of reversibly covalent dipeptidyl inhibitors of the SARS-CoV-2 main protease","volume":"66","author":"Geng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib105","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib106","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib107","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115979_bib108","article-title":"MPI8 is potent against SARS-CoV-2 by inhibiting dually and selectively the SARS-CoV-2 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115979_bib109","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/acsmedchemlett.2c00260","article-title":"A warhead substitution study on the coronavirus main protease inhibitor nirmatrelvir","volume":"13","author":"Vankadara","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib110","doi-asserted-by":"crossref","first-page":"10955","DOI":"10.1021\/acs.jmedchem.9b00875","article-title":"Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery","volume":"62","author":"Manevski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib111","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib112","article-title":"Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115979_bib113","series-title":"Preparation of Peptidomimetic Heteroaryl Ketones as SARS-CoV-2 3CL Protease Inhibitors and Methods for the Treatment of COVID-19","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib114","first-page":"2023","article-title":"Inhibition mechanism and antiviral activity of an \u03b1-ketoamide based SARS-CoV-2 main protease inhibitor","author":"Chen","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2023.115979_bib115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib116","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib117","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115979_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115979_bib121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2023.115979_bib122","doi-asserted-by":"crossref","first-page":"FSO853","DOI":"10.2144\/fsoa-2023-0020","article-title":"Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease","volume":"9","author":"Kuang","year":"2023","journal-title":"Future Science"},{"key":"10.1016\/j.ejmech.2023.115979_bib123","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acscentsci.1c00258","article-title":"Potent SARS-CoV-2 direct-acting antivirals provide an important complement to COVID-19 vaccines","volume":"7","author":"Pelly","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-023-01482-9","article-title":"Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment","volume":"8","author":"Jiang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115979_bib125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1039\/D2MD00344A","article-title":"Advances in research on 3C-like protease (3CL(pro)) inhibitors against SARS-CoV-2 since 2020","volume":"14","author":"Chen","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib126","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib127","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1473-3099(23)00132-9","article-title":"Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115979_bib128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115979_bib129","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115979_bib130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44259-023-00009-0","article-title":"Rapid resistance profiling of SARS-CoV-2 protease inhibitors","volume":"1","author":"Moghadasi","year":"2023","journal-title":"npj Antimicrobials and Resistance"},{"key":"10.1016\/j.ejmech.2023.115979_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib132","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1038\/s41467-023-40018-1","article-title":"In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir","volume":"14","author":"Kiso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib133","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2023.115979_bib135","series-title":"Triazine Derivative Having Virus Propagation Inhibitory Effect, and Pharmaceutical Composition","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib136","series-title":"3-triazolyl Methyl-1, 3, 5-triazine-2, 4-dione Compounds and Preparation Method and Application Thereof","first-page":"US11612603","year":"2023"},{"key":"10.1016\/j.ejmech.2023.115979_bib137","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40824-023-00357-y","article-title":"Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models","volume":"27","author":"Lee","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib138","doi-asserted-by":"crossref","first-page":"294","DOI":"10.7150\/ijbs.6.294","article-title":"Antiviral actions of flavanoid-derived compounds on dengue virus type-2","volume":"6","author":"Muhamad","year":"2010","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib139","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.3390\/molecules26133900","article-title":"Flavonoids as promising antiviral agents against sars-cov-2 infection: a mechanistic review","volume":"26","author":"Khazeei Tabari","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115979_bib140","series-title":"Pharmaceutical Application of Dimyricetin-Based Diselenide","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib141","series-title":"Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics","first-page":"2021","author":"Cao","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115979_bib142","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2023.115979_bib143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jmb.2005.09.012","article-title":"pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses","volume":"354","author":"Tan","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib144","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","article-title":"Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115979_bib145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/microorganisms9050893","article-title":"Baicalein and baicalin inhibit SARS-CoV-2 RNA-dependent-RNA polymerase","volume":"9","author":"Zandi","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2023.115979_bib146","series-title":"Preparation of Heterocyclic Derivatives as 3C like Protease Inhibitors","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115979_bib147","series-title":"Substituted Hydantoin Compounds, Methods for Preparation Thereof and Use Thereof in the Treatment And\/or Prevention of a Corona Virus Disease","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib148","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115979_bib149","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100582","article-title":"Structure-activity studies reveal scope for optimisation of ebselen-type inhibition of SARS-CoV-2 main protease","volume":"17","author":"Thun-Hohenstein","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115979_bib151","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2211688","article-title":"Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation","volume":"12","author":"Bei","year":"2023","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.115979_bib152","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.jcim.1c00851","article-title":"High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor","volume":"62","author":"Clyde","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115979_bib154","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib155","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib156","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib157","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.str.2021.06.002","article-title":"Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease","volume":"29","author":"Deshmukh","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2023.115979_bib158","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acsmedchemlett.1c00326","article-title":"Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (nirmatrelvir\/ritonavir): a new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115979_bib160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/vaccines11010107","article-title":"Paxlovid (nirmatrelvir and ritonavir) use in pregnant and lactating woman: current evidence and practice guidelines-a scoping review","volume":"11","author":"Chourasia","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2023.115979_bib161","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fchem.2021.819165","article-title":"Targeting SARS-CoV-2 proteases for COVID-19 antiviral development","volume":"9","author":"Lv","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib162","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/imt-2021-0168","article-title":"A global picture: therapeutic perspectives for COVID-19","volume":"14","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2023.115979_bib163","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1016\/j.apsb.2022.09.002","article-title":"Research and development of Chinese anti-COVID-19 drugs","volume":"12","author":"Ji","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115979_bib164","article-title":"Molecular basis for antiviral action of EDP-235: a potent and selective SARS-CoV-2 3CLpro inhibitor for the treatment of Covid 19","volume":"36","author":"Balakrishnan","year":"2022","journal-title":"FASEB (Fed. Am. Soc. Exp. Biol.) J."},{"key":"10.1016\/j.ejmech.2023.115979_bib165","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2023.115979_bib169","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic profiling of \u03b2-coronavirus 3CL Mpro protease ligand-binding sites","volume":"61","author":"Cho","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115979_bib170","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1107\/S2052252520012634","article-title":"Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M-pro: insights into enzyme mechanism and drug design","volume":"7","author":"Kneller","year":"2020","journal-title":"IUCrJ"},{"key":"10.1016\/j.ejmech.2023.115979_bib171","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1021\/bi400604t","article-title":"Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease","volume":"53","author":"Paasche","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115979_bib172","doi-asserted-by":"crossref","first-page":"10626","DOI":"10.1039\/D0SC02823A","article-title":"Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro by QM\/MM computational methods","volume":"11","author":"\u015awiderek","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2023.115979_bib173","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1021\/acscatal.0c05522","article-title":"Multiscale simulations of SARS-CoV-2 3CL protease inhibition with aldehyde derivatives. Role of protein and inhibitor conformational changes in the reaction mechanism","volume":"11","author":"Ramos-Guzm\u00e1n","year":"2021","journal-title":"ACS Catal."},{"key":"10.1016\/j.ejmech.2023.115979_bib174","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","volume":"42","author":"He","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115979_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: from bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2023.115979_bib176","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib177","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2023.115979_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"10.1016\/j.ejmech.2023.115979_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib180","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/antibiotics11121717","article-title":"A perspective on newly emerging proteolysis-targeting strategies in antimicrobial drug discovery","volume":"11","author":"Venkatesan","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2023.115979_bib181","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/vaccines11020270","article-title":"Recent advances in PROTAC-based antiviral strategies","volume":"11","author":"Ahmad","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2023.115979_bib182","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1080\/07391102.2021.1953601","article-title":"Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2","volume":"40","author":"Shaheer","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2023.115979_bib183","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib184","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115979_bib185","series-title":"Chimeric Conjugates for Degradation of Viral and Host Proteins and Methods of Use","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib186","series-title":"Preparation of Triazole Derivatives and its Application in the Preparation of 3 Chymotrypsin like Protease Inhibitor and Anti-coronavirus Drug","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib187","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115979_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102561","article-title":"Proteolysis targeting chimeras in non-small cell lung cancer","volume":"117","author":"Hagopian","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2023.115979_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216065","article-title":"PROTACs: promising approach for anticancer therapy","volume":"556","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115979_bib191","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2023.115979_bib192","series-title":"Synthesis of PROTACs Targeting Coronavirus 3cl Protease Treating SARS-CoV-2","first-page":"US11530195","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115979_bib193","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/fmc-2021-0208","article-title":"PROTAC cell permeability and oral bioavailability: a journey into uncharted territory","volume":"14","author":"Poongavanam","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib194","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib195","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115979_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib197","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib198","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1039\/D1MD00068C","article-title":"Recent advances in the development of covalent inhibitors","volume":"12","author":"Kim","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib199","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib200","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2023.115979_bib201","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115979_bib202","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of bruton's tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib203","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.chembiol.2021.03.005","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation","volume":"28","author":"Kiely-Collins","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115979_bib204","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115979_bib205","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115979_bib206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115979_bib207","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115979_bib208","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/dmd.114.061424","article-title":"The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib","volume":"43","author":"Shibata","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2023.115979_bib209","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib210","first-page":"1061","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies, Drug Discov","volume":"20","author":"Bauer","year":"2015","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2023.115979_bib211","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1021\/acs.jmedchem.2c00168","article-title":"Conformational constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine derivatives as new fourth-generation epidermal growth factor receptor inhibitors targeting T790M\/C797S mutations","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib212","article-title":"Abstract 43: discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115979_bib213","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.987467","article-title":"Global \u201cflu-ization\u201d of COVID-19: a perspective from Vietnam","volume":"10","author":"Nguyen","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2023.115979_bib214","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115979_bib215","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:58Z","timestamp":1777529158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":197,"alternative-id":["S0223523423009467"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115979","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115979"}}